NO974480L - Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme - Google Patents

Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme

Info

Publication number
NO974480L
NO974480L NO974480A NO974480A NO974480L NO 974480 L NO974480 L NO 974480L NO 974480 A NO974480 A NO 974480A NO 974480 A NO974480 A NO 974480A NO 974480 L NO974480 L NO 974480L
Authority
NO
Norway
Prior art keywords
vitamin
medicament
derivatives
manufacture
treatment
Prior art date
Application number
NO974480A
Other languages
English (en)
Other versions
NO974480D0 (no
Inventor
Joyce C Knutson
Richard B Mazess
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23645881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974480(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of NO974480D0 publication Critical patent/NO974480D0/no
Publication of NO974480L publication Critical patent/NO974480L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En fremgangsmåte til forebyggelse av tap av benmasse eller benmineralinnhold i et menneske som Vider av sekun(Jær hyperparathyroidisme ved å administrere en tilstrekkelig mengde av la-OH-vitamin D2; la,24(S)-(OH)2-vitamin D2; la-OH-vitamin D4; og la,24(R)-(OH)2-vitamin D4.
NO974480A 1995-04-03 1997-09-29 Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme NO974480L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/415,488 US5602116A (en) 1988-08-02 1995-04-03 Method for treating and preventing secondary hyperparathyroidism
PCT/US1996/004553 WO1996031215A1 (en) 1995-04-03 1996-04-03 Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Publications (2)

Publication Number Publication Date
NO974480D0 NO974480D0 (no) 1997-09-29
NO974480L true NO974480L (no) 1997-11-14

Family

ID=23645881

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974480A NO974480L (no) 1995-04-03 1997-09-29 Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme

Country Status (18)

Country Link
US (3) US5602116A (no)
EP (1) EP0820290B1 (no)
JP (1) JP3529790B2 (no)
KR (1) KR100432265B1 (no)
CN (1) CN1214795C (no)
AU (1) AU719773B2 (no)
BR (1) BR9604940A (no)
CA (1) CA2217260C (no)
DE (1) DE69629184T2 (no)
ES (1) ES2206570T3 (no)
FI (1) FI973868A0 (no)
HK (1) HK1008180A1 (no)
HU (1) HUP9801777A3 (no)
MX (1) MX9707535A (no)
NO (1) NO974480L (no)
NZ (1) NZ316662A (no)
PL (1) PL322613A1 (no)
WO (1) WO1996031215A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
NZ336924A (en) * 1997-02-13 2001-06-29 Bone Care Int Inc Targeted therapeutic delivery of vitamin D compounds via a Vitamin D conjugate
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
CA2326117A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2000015211A2 (en) * 1998-09-17 2000-03-23 Akesis Pharmaceuticals, Inc. Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
CA2401304A1 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
EP1334367B1 (en) * 2000-10-13 2006-06-07 Abbott Laboratories A method of determining the initial dose of vitamin d compounds
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
KR100438254B1 (ko) * 2001-03-29 2004-07-02 아이큐어 주식회사 비타민 ｄ 유사체를 포함하는 매트릭스형 경피흡수제제
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US20060189532A1 (en) * 2005-02-14 2006-08-24 Deluca Hector F Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US7566696B2 (en) 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004028515A1 (en) * 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
AU2004237439B2 (en) * 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
PL1622629T3 (pl) * 2003-05-07 2013-12-31 Osteologix As Kompozycja do kontrolowanego uwalniania zawierająca sól strontu
US20050239756A1 (en) * 2004-04-23 2005-10-27 Bone Care International, Inc. Methods of treating various vitamin D metabolism conditions with 1alpha-hydroxyvitamin D2
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
EP1945185B1 (en) * 2005-10-12 2016-02-03 Proventiv Therapeutics, LLC Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
US9750715B2 (en) * 2006-01-30 2017-09-05 Panion & Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
PT2679228T (pt) * 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
PT2148684E (pt) * 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2008134518A2 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2009124210A1 (en) 2008-04-02 2009-10-08 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
MX2012000892A (es) 2009-07-21 2012-06-01 Keryx Biopharmaceuticals Inc Formas de dosificacion de citrato ferrico.
CN102711789B (zh) 2009-07-29 2018-06-08 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂
US7886904B1 (en) * 2009-07-30 2011-02-15 Owens Corning Intellectual Capital, Llc Loosefill package for blowing wool machine
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
WO2011130669A1 (en) * 2010-04-16 2011-10-20 Baxter International Inc. Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
PT2717896T (pt) 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
US20140315809A1 (en) 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2015223908C1 (en) * 2014-02-26 2020-12-03 Nippon Zoki Pharmaceutical Co., Ltd. Progress-Suppressing or Improving Agent for Chronic Kidney Disease
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
JP6520510B2 (ja) * 2015-07-15 2019-05-29 富士ゼロックス株式会社 情報処理装置及び情報処理プログラム
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
CA2069084C (en) * 1990-09-21 2007-05-22 Joyce C. Knutson 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues
EP0550702B1 (en) * 1991-01-08 1999-05-06 Bone Care International, Inc. METHODS FOR PREPARATION AND USE OF 1$g(a),24-DIHYDROXY VITAMIN D 2?
JP3030157B2 (ja) * 1991-03-13 2000-04-10 株式会社クラレ シクロヘキサントリオール誘導体
DE69318142T2 (de) * 1992-01-29 1998-09-17 Bone Care Int Inc 1 alpha-HYDROXY-24-(EPI)-VITAMIN D4
EP0562497A1 (en) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
JP3179495B2 (ja) * 1992-08-28 2001-06-25 ボーン ケア インターナショナル インコーポレイテッド １α，２４（Ｓ）−ジヒドロキシビタミンＤ▲下２▼の調製及び使用方法
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure

Also Published As

Publication number Publication date
US5861386A (en) 1999-01-19
FI973868A (fi) 1997-10-02
NO974480D0 (no) 1997-09-29
FI973868A0 (fi) 1997-10-02
HUP9801777A3 (en) 1999-05-28
CA2217260A1 (en) 1996-10-10
EP0820290B1 (en) 2003-07-23
PL322613A1 (en) 1998-02-02
CA2217260C (en) 2000-08-01
EP0820290A1 (en) 1998-01-28
WO1996031215A1 (en) 1996-10-10
DE69629184T2 (de) 2004-05-06
NZ316662A (en) 2001-04-27
CN1214795C (zh) 2005-08-17
JP3529790B2 (ja) 2004-05-24
US5707980A (en) 1998-01-13
KR100432265B1 (ko) 2004-09-10
ES2206570T3 (es) 2004-05-16
HUP9801777A2 (hu) 1998-11-30
KR19980703537A (ko) 1998-11-05
BR9604940A (pt) 1998-06-09
AU5384096A (en) 1996-10-23
AU719773B2 (en) 2000-05-18
DE69629184D1 (de) 2003-08-28
MX9707535A (es) 1998-07-31
CN1185109A (zh) 1998-06-17
JPH11503164A (ja) 1999-03-23
HK1008180A1 (en) 1999-05-07
US5602116A (en) 1997-02-11

Similar Documents

Publication Publication Date Title
NO974480L (no) Anvendelse av vitamin D2 eller vitamin D4 derivater til fremstilling av et medikament for behandling av sekundær hyperparathyreoidisme
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
NO952372L (no) Fremgangsmåte og apparatur for å oppnå solbrunhet uten soling
BG102726A (en) Combined therapy for osteoporosis
SE9404196D0 (sv) New antithrombotic formulation
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
AU3717395A (en) Compositions for the treatment of skin disorders
AU6857887A (en) Therapeutic agent
WO1999009964A3 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektion
EP1632248B8 (en) Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness
NZ335078A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
AU8853998A (en) Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
GB2314019A8 (en) L-lysine tablets for treating hair loss
EP0283840A3 (en) Mycoplasma hyopneumoniae antigen and uses therefor
EP0756869A3 (en) Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
BG102667A (en) Diosgenine-containing composition
ZA949563B (en) Method for treating aphthae using dimeticone.
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
UA43399C2 (uk) Композиція для гігієни, профілактики і лікування захворювань порожнини рота
AU6206698A (en) Isoflavone derivatives, processes for the preparation thereof and pharmac euticalcompositions containing them
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
HK1005651A1 (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application